Stay updated on Pembrolizumab Combo in Metastatic NSCLC Clinical Trial
Sign up to get notified when there's something new on the Pembrolizumab Combo in Metastatic NSCLC Clinical Trial page.

Latest updates to the Pembrolizumab Combo in Metastatic NSCLC Clinical Trial page
- ChecktodayChange DetectedSome ancillary NIH grant and MedlinePlus topic references were removed from the study page. The site revision label changed from v3.8.0 to v3.8.1.SummaryDifference0.1%

- Check7 days agoNo Change Detected
- Check14 days agoChange DetectedThe record for a Phase 2 metastatic non-small cell lung cancer study is displayed, with details on pembrolizumab plus epacadostat versus pembrolizumab plus placebo, participant criteria, outcomes, and study locations.SummaryDifference95%

- Check21 days agoChange DetectedThe footer revision label changes from v3.7.2 to v3.8.0, while the study record continues to show a 403 Forbidden error.SummaryDifference0.3%

- Check28 days agoChange DetectedThe clinical trial record for pembrolizumab plus epacadostat versus pembrolizumab plus placebo in metastatic non-small cell lung cancer is now displayed. It includes study design and results measures, participant criteria, international locations, record dates, and study documents.SummaryDifference99%

- Check35 days agoChange DetectedThe footer’s site revision changed from v3.7.1 to v3.7.2; the page continues to display a 403 error.SummaryDifference0.2%

- Check42 days agoChange DetectedThe ClinicalTrials.gov error page’s footer now displays revision v3.7.1 instead of v3.7.0.SummaryDifference0.2%

Stay in the know with updates to Pembrolizumab Combo in Metastatic NSCLC Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pembrolizumab Combo in Metastatic NSCLC Clinical Trial page.